On July 9, 2026 NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, reported the launch of PTEN IHC CDx, the first immunohistochemistry (IHC) companion diagnostic test approved by the U.S. Food and Drug Administration (FDA) for patients with prostate adenocarcinoma. The test identifies PTEN protein loss, also known as PTEN deficiency, in patients who may be eligible for AstraZeneca’s recently approved targeted therapy TRUQAP (capivasertib).1

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

PTEN IHC CDx extends the company’s reach into urologic oncology, where community practices manage the majority of patients with advanced prostate cancer. Performed by NeoGenomics’ pathologists across its national oncology laboratory network, the test is available as a standalone order or as part of NEO PanTracer Pro for prostate cancer, a comprehensive molecular workup that combines CGP and cancer-type-directed IHC testing in a single order built to evolve with new treatment options.

"Clinicians treating this aggressive form of prostate cancer have long needed both a targeted therapy and a validated way to identify eligible patients," said Nathan Montgomery, Vice President, Medical Services, NeoGenomics. "With PTEN IHC CDx now integrated into NEO PanTracer Pro, community oncology practices have an FDA-approved companion diagnostic available through a single national laboratory partner, reflecting our commitment to providing the tools clinicians need for timely treatment decisions when new therapies become available."

Prostate cancer is the most common cancer in men in the United States, with more than 300,000 new cases and over 36,000 deaths annually.2 Of the approximately 35,000 patients diagnosed each year with mAPMN/S prostate cancer (formerly mHSPC), about one in four – or approximately 8,750 patients – have PTEN-deficient tumors.2,3 PTEN protein loss is detectable through a tissue-based test at the time of diagnosis.4

About PTEN IHC CDx
NeoGenomics’ IHC companion diagnostic assay detects PTEN protein loss in prostate adenocarcinoma tissue using the VENTANA PTEN (SP218) RxDx Assay. Authorized by the FDA to identify patients with mAPMN/S prostate cancer who may be eligible for TRUQAP, the test is performed by NeoGenomics pathologists across its national oncology laboratory network. PTEN IHC CDx is available as a standalone order, delivering results in as few as one to two days, or as part of NEO PanTracer Pro for prostate cancer, a comprehensive molecular workup offered in a single coordinated order that integrates CGP with cancer-type-directed IHC and ancillary testing for prostate carcinoma. The test has been approved in New York State.

(Press release, NeoGenomics Laboratories, JUL 9, 2026, View Source [SID1234669131])